ABCC6

Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Tuesday, November 7, 2023

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the third quarter ended September 30, 2023 and provided business highlights.

Key Points: 
  • Patient recruitment is underway, and the Company remains on track to report topline data in mid-2025.
  • Exploratory efficacy data reported suggested clinical benefit for ENPP1 Deficiency, including improvement in key biomarkers, patient-reported outcomes (PROs), and functional outcomes.
  • R&D Expenses were $13.3 million for the quarter ended September 30, 2023, compared to $12.2 million for the prior-year period.
  • Net loss was $16.6 million, or $0.29 loss per share, for the quarter ended September 30, 2023, compared to $16.4 million, or $0.38 loss per share, for the prior-year period.

Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions

Retrieved on: 
Tuesday, October 10, 2023

“We commend Genomics England for recognizing the crucial importance of early detection of GACI as we advance INZ-701 into clinical trials in infants.

Key Points: 
  • “We commend Genomics England for recognizing the crucial importance of early detection of GACI as we advance INZ-701 into clinical trials in infants.
  • Genomics England collaborated with NHS experts as well as scientists, healthcare professionals (HCPs), and people living with rare conditions to select 223 individual conditions for its current screening program.
  • Inozyme is developing INZ-701, an enzyme replacement therapy, for the treatment of rare disorders like GACI that impact the vasculature, soft tissue, or skeleton.
  • To learn more about Genomics England and its Generation Study, read the full announcement here .

Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress

Retrieved on: 
Monday, January 9, 2023

BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will share topline pharmacokinetic, pharmacodynamic (PK/PD) and safety data from the ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency at a virtual Investor and Analyst Event on Thursday, Feb. 16, 2023.

Key Points: 
  • We also saw promising PPi elevation in our ABCC6 Deficiency trial, with a rapid initial increase at the lowest dose of INZ-701.
  • The Company will share topline pharmacokinetic, pharmacodynamic (PK/PD) and safety data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency.
  • The event will also feature presentations from members of the Inozyme management team, as well as from key opinion leaders in ENPP1 Deficiency and ABCC6 Deficiency.
  • The webcast will be accessible through the Investor Relations section of Inozyme’s website under events and will be available for a limited time following the event.

Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, November 10, 2022

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the third quarter ended September 30, 2022 and provided recent business highlights.

Key Points: 
  • Preclinical data supporting INZ-701's potential to treat intimal proliferation was featured at the International Vascular Biology Meeting (IVBM) 2022 Annual Meeting in October.
  • Cash Position and Financial Guidance Cash, cash equivalents, and investments were $141.5 million as of September 30, 2022.
  • Research and Development (R&D) Expenses R&D expenses were$12.2 millionfor the quarter ended September 30, 2022, compared to$9.3 millionfor the prior-year period.
  • General and Administrative (G&A) Expenses G&A expenses were$4.7 millionfor the quarter ended September 30, 2022, compared to$4.9 millionfor the prior-year period.

Inozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Tuesday, September 6, 2022

BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference.

Key Points: 
  • BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference.
  • The prerecorded presentation will become available on-demand on Monday, September 12, 2022, at 7:00 AM ET.
  • A replay of the presentation can be accessed from the Investor Relations section of Inozymes website and will be available for a limited time following the event.
  • Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton.

Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures

Retrieved on: 
Tuesday, July 26, 2022

Together with our financing, this debt facility further strengthens our balance sheet and provides strategic and operational flexibility, said Sanjay Subramanian, M.S., MBA, Inozymes chief financial officer.

Key Points: 
  • Together with our financing, this debt facility further strengthens our balance sheet and provides strategic and operational flexibility, said Sanjay Subramanian, M.S., MBA, Inozymes chief financial officer.
  • Our partnership with K2HV reduces our dependence on capital markets allowing us to focus on our mission of helping patients suffering from diseases of abnormal mineralization.
  • Under the terms of the agreement, Inozyme drew $5 million from K2HV upon execution of the loan agreement, and has an option to draw down an additional $20 million from the first tranche through March 31, 2023.
  • K2 HealthVentures is an alternative investment firm focused on providing flexible, long-term financing solutions to innovative private and public companies in the life sciences and healthcare industries.

Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)

Retrieved on: 
Tuesday, July 19, 2022

BOSTON, July 19, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced positive preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three subjects treated in the Phase 1 portion of its ongoing Phase 1/2 clinical trial of INZ-701 in adult subjects with ABCC6 Deficiency, which presents as pseudoxanthoma elasticum (PXE) in older individuals. At the 0.2 mg/kg dose level of INZ-701, all three subjects showed rapid and significant increases in PPi levels. In preclinical models, PPi was shown to be a key predictive biomarker of therapeutic benefit in ABCC6 Deficiency.

Key Points: 
  • Preliminary PK and INZ-701 enzymatic activity remained consistent with data previously reported from the Companys ongoing Phase 1/2 trial of INZ-701 in subjects with ENPP1 Deficiency.
  • The Company plans to report topline data from the ongoing Phase 1/2 clinical trial in ABCC6 Deficiency in the first quarter of 2023.
  • INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.
  • INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.

Inozyme Pharma Announces Partnership with Rady Children’s Institute for Genomic Medicine to Advance Newborn Screening for Genetic Diseases

Retrieved on: 
Thursday, June 16, 2022

We look forward to working with Rady Childrens Institute for Genomic Medicine, and with the BeginNGS consortium, to advance the use of this promising screening technology.

Key Points: 
  • We look forward to working with Rady Childrens Institute for Genomic Medicine, and with the BeginNGS consortium, to advance the use of this promising screening technology.
  • We are thrilled at the prospect of newborn screening to assist in early identification of infants affected by ENPP1 Deficiency and ABCC6 Deficiency via Inozymes collaboration with Rady Childrens Institute for Genomic Medicine.
  • Rady Childrens Institute for Genomic Medicine is transforming pediatric critical care by advancing disease-specific healthcare for infants and children with rare disease.
  • These statements include, but are not limited to, statements relating the partnership with Rady Childrens Institute for Genomic Medicine.

Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, June 7, 2022

BOSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the appointment of Kurt Gunter, M.D., as chief medical officer.

Key Points: 
  • BOSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the appointment of Kurt Gunter, M.D., as chief medical officer.
  • Dr. Gunter, who most recently served as chief medical officer, cell therapy, and head of regulatory affairs at Athenex, brings to Inozyme over 30 years of expertise in regulatory affairs, clinical development, and government relations.
  • It is a pleasure to welcome Kurt to the Inozyme team to lead Inozymes clinical development and regulatory strategy, said Axel Bolte, MSc, MBA, Inozymes co-founder, president, and chief executive officer.
  • Prior to Athenex, Dr. Gunter served as chief medical officer at Kuur Therapeutics (formerly Cell Medica), where he headed the medical affairs, clinical operations, and regulatory affairs departments.

Inozyme Pharma to Present at the 2022 Jefferies Healthcare Conference

Retrieved on: 
Wednesday, June 1, 2022

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the companys co-founder, president, and chief executive officer, will present at the Jefferies Healthcare Conference.

Key Points: 
  • BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the companys co-founder, president, and chief executive officer, will present at the Jefferies Healthcare Conference.
  • The presentation will take place on Wednesday, June 8, 2022 at 2:30 PM ET.
  • Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton.
  • Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University.